Hlk Sp. z o.o.

The site focuses on conditions affecting women's reproductive health, such as endometriosis and its associated pain, while also exploring strategies for the prevention of pregnancy. Clinical studies aim to improve symptom control and offer new therapeutic options for affected women.

• Endometriosis
• Endometriosis related pain
• Prevention of pregnancy

Hlk Sp. z o.o., operating through the Centrum Medyczne Chodźki in Lublin, conducts trials that evaluate novel drugs and delivery systems to enhance quality of life for patients with these urogenital conditions.

Research at this centre addresses a broad spectrum of cancers, ranging from advanced solid tumors and cervical cancer to hematologic malignancies and melanoma. The trials are designed to test innovative therapies that could slow disease progression and improve survival outcomes.

• Advanced Solid Tumor
• Cervical Cancer
• Diffuse large B cell lymphoma
• Esophageal Cancer
• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma
• Gastrointestinal cancer
• Gynecological cancer
• Hematological cancer
• Melanoma
• Multiple Myeloma
• Non-Hodgkin Lymphoma
• Non‑small cell lung cancer

The commercial organisation leverages its pharmaceutical expertise to bring forward promising anticancer agents, seeking to expand treatment options across multiple tumor types.

Studies in this area examine normal and pathological processes of the reproductive and urinary systems. Trials evaluate products such as the LVDS (Levonorgestrel Vaginal Delivery System), the investigational molecule AMY109, and the enzyme inhibitor vipoglanstat, with goals of enhancing contraceptive reliability and alleviating endometriosis symptoms.

• Contraceptive efficacy
• Endometriosis treatment
• Hormonal regulation studies
• Urinary health assessments

By integrating clinical research with its commercial operations, Hlk Sp. z o.o. contributes to advancing therapeutic options that support both reproductive health and urinary system function.